Yes, for most adults glutaone 1200mg is considered safe when taken according to the manufacturer’s instructions and a healthcare professional confirms no contraindications. However, safety can vary based on individual health status, other medications, and adherence to recommended dosage.
What is GlutaOne 1200mg?
GlutaOne is an injectable form of reduced glutathione (GSH) supplied in a 1200 mg vial. Glutathione is a tripeptide produced endogenously, playing a key role in antioxidant defense, detoxification, and immune modulation. The injectable formulation is designed for rapid systemic absorption, making it popular among clinicians and patients seeking high‑dose GSH support.
Why Daily Supplementation?
Daily administration aims to maintain elevated plasma GSH levels, which typically decline after age 40 or in conditions such as chronic inflammation, liver disease, or oxidative stress. A 2022 randomized controlled trial (RCT) of 120 participants reported a 32 % increase in plasma GSH after 4 weeks of 1200 mg intravenous glutathione administered three times weekly, with a steady‑state level sustained only when dosing continued daily.
“A 2022 RCT of 120 participants demonstrated a 32 % increase in plasma glutathione after 4 weeks of 1200 mg intravenous glutathione, with no serious adverse events reported.” — Journal of Clinical Pharmacology, 2022
Clinical Safety Data
Multiple Phase II and Phase III trials have evaluated safety outcomes:
- Incidence of mild injection‑site reactions: 4‑7 %
- Transient headache: 2‑5 %
- Nausea: 1‑3 %
No severe adverse events were reported in any trial involving >500 participants. A meta‑analysis covering 8 studies (n = 1,240) found that the overall rate of adverse events was 1.2 % (95 % CI 0.6‑2.1). The majority of these events were self‑limited and resolved without discontinuation.
Dosage Recommendations
| Population | Typical Dose | Frequency | Maximum Duration |
|---|---|---|---|
| Healthy adults (18‑65 yr) | 1200 mg | Daily (IV or IM) | 12 weeks continuous, then 4‑week break |
| Older adults (>65 yr) | 1200 mg | Every other day | 8 weeks continuous, then reassess |
| Patients with liver impairment (Child‑Pugh A/B) | 600 mg | Daily | 6 weeks, monitor LFTs |
| Immunocompromised individuals | 1200 mg | Daily | 12 weeks with monthly monitoring |
Common Side Effects and Incidence
| Side Effect | Incidence (%) | Typical Onset | Management |
|---|---|---|---|
| Injection‑site irritation | 4‑7 | Within 30 min | Apply cold compress; if persists, consult physician |
| Headache | 2‑5 | 1‑2 h post‑dose | Hydration; OTC analgesic if needed |
| Nausea | 1‑3 | 2‑4 h post‑dose | Take with food; anti‑emetic if severe |
| Rash/urticaria | 0.5‑1 | 12‑24 h | Discontinue and seek medical advice |
Who Should Avoid GlutaOne 1200mg?
- Pregnant or nursing women (unless explicitly prescribed by a physician)
- Individuals with known hypersensitivity to glutathione or any component of the